Who We Are

We are a statistical consulting company specializing in the application of statistics to medical research and clinical trials. We are also experienced in the use of statistics in many other areas including epidemiology, psychology and survey design.

Services

Assistance with research design and data collection methodology

Screen data to detect inconsistencies

Statistical analysis
of data

Written report with statistical methods, tables and figures

Publications

Ben-Porat L, Panageas KS, Hanlon C, Patel A, Halpern A, Houghton AN, Coit G. Estimates of Stage Specific Survival are Altered by the Changes in the 2002 AJCC Staging for Melanoma. Cancer. 2006 Jan 1;106(1):163-71.

Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, Deangelis LM. Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. J Clin Oncol. 2006 Dec 20;24(36):5711-5.

Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P; HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother. 2009 Oct;58(10):1701-13.

Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM. Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother. 2010 Oct;59(10):1489-501.

Hwa C, Price LS, Belitskaya-Levy I, Ma MW, Shapiro RL, Berman RS, Kamino H, Darvishian F, Osman I, Stein JA. Single versus multiple primary melanomas: old questions and new answers. Cancer. 2012 Sep 1;118(17).

Zellnet_Logo_neu_klein

Contact Us